Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 37

Sort by

Sort Order Select

Journal Articles

Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Katharina Rothe, PhD, Xiaojia Niu, PhD, Min Chen, PhD, Rick Li, Sungeun Nam, Xiuyan Zhang, German Novakovskiy, Yehyeon Ahn, Shenshen Lai, Hong Zhang, PhD, Jun Yan, Hong Liu, Yun Zhao, PhD, Depei Wu, MDPhD, Yubin Ge, PhD, Wyeth W. Wasserman, Calvin K. Yip, Zaihui Zhang, PhD, Xiaoyan Jiang, MD PhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-140595

Published: 2020

Journal Articles

Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Therapy-Resistant CML Stem/Progenitor Cells

Andrew Wu, BSc, Min Chen, PhD, Ryan Yen, BSc, Xiaoyan Jiang, MD PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140459

Published: 2020

Journal Articles

The AHI-1-BCR-ABL-DNM2 Complex Mediates Mitochondrial Dynamics in Drug-Resistant BCR-ABL + Cells

Ryan Yen, BSc, Lambert Yue, BSc, Steven Pelech, PhD, Xiaoyan Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 189.

https://doi.org/10.1182/blood-2019-128712

Published: 2019

Journal Articles

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Andrew Wu, BSc, Katharina Rothe, PhD, Min Chen, PhD, Hanyang Lin, PhD, Artem Babaian, PhD, Ryan Yen, BSc, Donna L. Forrest, MD, Xiaoyan Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 4138.

https://doi.org/10.1182/blood-2019-127826

Published: 2019

Journal Articles

Global Transcriptome Profiling Identifies a Key Mir-185-PAK6 Axis That Promotes Survival of Leukemic Stem Cells and Drug-Insensitive Blasts in BCR-ABL + Human Leukemia

Andrew Wu, BSc, Lin Hanyang, PhD, Katharina Rothe, PhD, Min Chen, MD PhD, Jens Ruschmann, PhD, Oleh Petriv, PhD, Kieran O'Neill, PhD, Tobias Maetzig, MD, David Knapp, PhD, Naoto Nakamichi, MD PhD, Ryan Brinkman, PhD, Inanc Birol, PhD, Donna L Forrest, MD, Carl Hansen, PhD, R. Keith Humphries, MD PhD, Connie J. Eaves, PhD, Xiaoyan Jiang, MD PhD

Blood (2018) 132 (Supplement 1): 931.

https://doi.org/10.1182/blood-2018-99-113559

Published: 2018

Journal Articles

Loss of Ahi-1 Impairs the Self-Renewal Activity of Normal and BCR-ABL + Stem Cells in Vitro and in Vivo

Min Chen, Kevin Lin, PhD, Xiaoyan Jiang, MD PhD

Blood (2017) 130 (Supplement 1): 2516.

https://doi.org/10.1182/blood.V130.Suppl_1.2516.2516

Published: 2017

Journal Articles

Targeting the GAS6/AXL Pathway with a Newly Developed AXL-Selective Inhibitor SLC-0211 for the Treatment of Acute Myeloid Leukemia

Xiaojia Niu, Katharina Roche, PhD, Min Chen, MD PhD, Hong Zhang, PhD, Jun Yan, Yubin Ge, PhD, Zaihui Zhang, PhD, Xiaoyan Jiang, MD PhD

Blood (2017) 130 (Supplement 1): 2640.

https://doi.org/10.1182/blood.V130.Suppl_1.2640.2640

Published: 2017

Journal Articles

Drug-Insensitive CML Stem/Progenitor Cells Highly Express Key Regulators of the Hedgehog Pathway and Inhibition of the Hedgehog Pathway Enhances Their Response to TKI Treatment

Kelly A. Turner, BSc, Katharina Rothe, PhD, Adrian Woolfson, MD PhD, Xiaoyan Jiang, MD PhD

Blood (2016) 128 (22): 4236.

https://doi.org/10.1182/blood.V128.22.4236.4236

Published: 2016

Journal Articles

Enhanced and Accelerated Repopulation of Mutant C-Kit Immunodeficient Mice By Transplants of Primary Chronic and Acute Myeloid Leukemic Human Cells

Naoto Nakamichi, MD PhD, Colin A. Hammond, Paul H. Miller, PhD, Katharina Rothe, PhD, Philip A Beer, BM, MRCP, MRCPath, Xiaoyan Jiang, MD PhD, Michael W. Deininger, MD PhD, Connie J. Eaves, PhD

Blood (2016) 128 (22): 4537.

https://doi.org/10.1182/blood.V128.22.4537.4537

Published: 2016

Journal Articles

PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia

Gang Xiao, PhD, Zhengshan Chen, MD PhD, Brass Daniel, PhD, Lai N Chan, PhD, Huimin Geng, PhD, Xiaoyan Jiang, MD PhD, Markus Müschen, MD PhD

Blood (2016) 128 (22): 1056.

https://doi.org/10.1182/blood.V128.22.1056.1056

Published: 2016

Journal Articles

The Focal Adhesion Complex Ilk-Pinch-Parvin Is Key to Niche Interactions and Survival of Quiescent Stem Cells in Chronic Myeloid Leukemia In Vitro and In Vivo

Katharina Rothe, PhD, Artem Babaian, Naoto Nakamichi, MD PhD, Min Chen, PhD, Akie Watanabe, Dixie Mager, PhD, Connie J. Eaves, PhD, Shoukat Dedhar, PhD, Xiaoyan Jiang, MD PhD

Blood (2016) 128 (22): 936.

https://doi.org/10.1182/blood.V128.22.936.936

Published: 2016

Journal Articles

The Role Of BIN1 Tumor Suppressor Isoforms In Regulation Of Proliferation, Apoptosis and Tumor Formation Of Human Cutanous T-Cell Lymphoma Cells In Vitro and In Vivo

Sharmin Esmailzadeh, Youwen Zhou, Xiaoyan Jiang, MD, PhD

Blood (2013) 122 (21): 2517.

https://doi.org/10.1182/blood.V122.21.2517.2517

Published: 2013

Journal Articles

Effectively Targeting Treatment-Naïve CML Stem/Progenitor Cells From Imatinib-Nonresponders With Combination Treatments Of JAK2 and ABL Inhibitors In Vitro and In Vivo

Hanyang Lin, MSc, Min Chen, PhD, Katharina Rothe, MSc, Matthew V Lorenzi, PhD, Adrian Woolfson, BM BCh, PhD, Xiaoyan Jiang, MD, PhD

Blood (2013) 122 (21): 1474.

https://doi.org/10.1182/blood.V122.21.1474.1474

Published: 2013

Journal Articles

Identification of a Unique Autophagy Gene Expression Signature in CD34 + CML Stem/Progenitor Cells That Correlates with Clinical Response to Imatinib Mesylate

Katharina Rothe, Kevin B.L. Lin, Hanyang Lin, Amy Leung, Donna L. Forrest, MD, FRCPC, Sharon Gorski, Xiaoyan Jiang, MD, PhD

Blood (2012) 120 (21): 1662.

https://doi.org/10.1182/blood.V120.21.1662.1662

Published: 2012

Journal Articles

Targeting Treatment-Naïve CML Stem/Progenitor Cells From Imatinib-Nonresponders with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy

Hanyang Lin, Katharina Rothe, Matthew V Lorenzi, PhD, Adrian Woolfson, BM BCh, PhD, Xiaoyan Jiang, MD, PhD

Blood (2012) 120 (21): 1339.

https://doi.org/10.1182/blood.V120.21.1339.1339

Published: 2012

Journal Articles

Longterm Serial Transplantability of BCR-ABL+ Chronic Phase CML Cells Is Predicted by a 6-Week LTC-IC Assay.

Ivan Sloma, PharmD, PhD, Philip A Beer, BM, MRCP, MRCPath, Kyi Min Saw, Matthiew Chan, Karen Lambie, Bobby Johnston, Xiaoyan Jiang, MD, PhD, Connie J. Eaves, PhD

Blood (2012) 120 (21): 2770.

https://doi.org/10.1182/blood.V120.21.2770.2770

Published: 2012

Journal Articles

Targeting the CML Stem/Progenitor Cell with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy

Hanyang Lin, Matthew Lorenzi, PhD, Adrian Woolfson, PhD, Xiaoyan Jiang, MD, PhD

Blood (2011) 118 (21): 2743.

https://doi.org/10.1182/blood.V118.21.2743.2743

Published: 2011

Journal Articles

Molecular and Structural Characterization of the SH3 Domain of AHI-1 in Regulation of Cellular Resistance of BCR-ABL + Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors

Xiaohu Liu, Min Chen, PhD, Paolo Lobo, Jianghong An, Ph.D., SW. Grace Cheng, Annie Moradian, Gregg B. Morin, PhD, Filip Van Petegem, PhD, Xiaoyan Jiang, MD, PhD

Blood (2011) 118 (21): 966.

https://doi.org/10.1182/blood.V118.21.966.966

Published: 2011

Journal Articles

Characterization of the Role of the Tumor Suppressor BIN1 as a Potential Mediator of the AHI-1 Oncogene in Human Cutaneous T-Cell Lymphomas

Sharmin Esmailzadeh, Helena Wang, Xiaoyan Jiang, MD, PhD

Blood (2011) 118 (21): 5229.

https://doi.org/10.1182/blood.V118.21.5229.5229

Published: 2011

Journal Articles

Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells.

Donna DeGeer, MSc, Paolo Gallipoli, MD, Min Chen, PhD, Ivan Sloma, PhD, Heather Jorgensen, PhD, Donna Forrest, MD, Karen Lambie, Helen Nakamoto, Kyi Min Saw, Matthew Chan, Kathleen Newmarch, Leon Zhou, Ali G. Turhan, MD, PhD, Ralph B. Arlinghaus, PhD, Allen C. Eaves, MD, FRCPC, PhD, Connie J. Eaves, PhD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Xiaoyan Jiang, MD, PhD

Blood (2010) 116 (21): 3404.

https://doi.org/10.1182/blood.V116.21.3404.3404

Published: 2010

NARROW

Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Therapy-Resistant CML Stem/Progenitor Cells

The AHI-1-BCR-ABL-DNM2 Complex Mediates Mitochondrial Dynamics in Drug-Resistant BCR-ABL + Cells

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Global Transcriptome Profiling Identifies a Key Mir-185-PAK6 Axis That Promotes Survival of Leukemic Stem Cells and Drug-Insensitive Blasts in BCR-ABL + Human Leukemia

Loss of Ahi-1 Impairs the Self-Renewal Activity of Normal and BCR-ABL + Stem Cells in Vitro and in Vivo

Targeting the GAS6/AXL Pathway with a Newly Developed AXL-Selective Inhibitor SLC-0211 for the Treatment of Acute Myeloid Leukemia

Drug-Insensitive CML Stem/Progenitor Cells Highly Express Key Regulators of the Hedgehog Pathway and Inhibition of the Hedgehog Pathway Enhances Their Response to TKI Treatment

Enhanced and Accelerated Repopulation of Mutant C-Kit Immunodeficient Mice By Transplants of Primary Chronic and Acute Myeloid Leukemic Human Cells

PP2A Balances Glucose Metabolism and Foxo Activation to Maintain Cellular Redox Homeostasis in Acute Lymphoblastic Leukemia

The Focal Adhesion Complex Ilk-Pinch-Parvin Is Key to Niche Interactions and Survival of Quiescent Stem Cells in Chronic Myeloid Leukemia In Vitro and In Vivo

The Role Of BIN1 Tumor Suppressor Isoforms In Regulation Of Proliferation, Apoptosis and Tumor Formation Of Human Cutanous T-Cell Lymphoma Cells In Vitro and In Vivo

Effectively Targeting Treatment-Naïve CML Stem/Progenitor Cells From Imatinib-Nonresponders With Combination Treatments Of JAK2 and ABL Inhibitors In Vitro and In Vivo

Identification of a Unique Autophagy Gene Expression Signature in CD34 + CML Stem/Progenitor Cells That Correlates with Clinical Response to Imatinib Mesylate

Targeting Treatment-Naïve CML Stem/Progenitor Cells From Imatinib-Nonresponders with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy

Longterm Serial Transplantability of BCR-ABL+ Chronic Phase CML Cells Is Predicted by a 6-Week LTC-IC Assay.

Targeting the CML Stem/Progenitor Cell with JAK2 (BMS-911543)/ABL Inhibitor Combination Therapy

Molecular and Structural Characterization of the SH3 Domain of AHI-1 in Regulation of Cellular Resistance of BCR-ABL + Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitors

Characterization of the Role of the Tumor Suppressor BIN1 as a Potential Mediator of the AHI-1 Oncogene in Human Cutaneous T-Cell Lymphomas

Combined Targeting of BCR-ABL and JAK2 with ABL and JAK2 Inhibitors Is Effective Against CML Patients' Leukemic Stem/Progenitor Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only